Individualized pharmacological treatment of neuropathic pain

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 2, 2015, Pages 135-142

  Helfert, S M ^a   Reimer, M ^a   Hoper J ^a   Baron, R ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; CAPSAICIN; MENTHOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SODIUM CHANNEL BLOCKING AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL PRACTICE; ELECTROSTIMULATION; HUMAN; LONG TERM CARE; LONG TERM POTENTIATION; MONOTHERAPY; NEUROPATHIC PAIN; PAIN; PHENOTYPE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOMATOSENSORY SYSTEM; TREATMENT RESPONSE; CLASSIFICATION; NEURALGIA; PAIN MEASUREMENT; PERSONALIZED MEDICINE; PROCEDURES;

ANALGESICS; HUMANS; INDIVIDUALIZED MEDICINE; NEURALGIA; PAIN MEASUREMENT; PHENOTYPE;

EID: 84927169928     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.19     Document Type: Article

References (75)

1. Max, M.B. Towards physiologically based treatment of patients with neuropathic pain. Pain 42, 131-137 (1990).
2. Woolf, C.J. et al. Towards a mechanism-based classification of pain? Pain 77, 227-229 (1998).
3. von Hehn, C.A., Baron, R. & Woolf, C.J. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 73, 638-652 (2012).
4. Lai, J., Hunter, J.C. & Porreca, F. The role of voltage-gated sodium channels in neuropathic pain. Curr. Opin. Neurobiol. 13, 291-297 (2003).
5. Siqueira, S.R., Alves, B., Malpartida, H.M., Teixeira, M.J. & Siqueira, J.T. Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia. Neuroscience 164, 573-577 (2009).
6. Woolf, C.J. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 152(3 suppl), S2-S15 (2011).
7. Treede, R.D. et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 70, 1630-1635 (2008).
8. Klein, T., Magerl, W., Rolke, R. & Treede, R.D. Human surrogate models of neuropathic pain. Pain 115, 227-233 (2005).
9. Staahl, C., Olesen, A.E., Andresen, T., Arendt-Nielsen, L. & Drewes, A.M. Assessing analgesic actions of opioids by experimental pain models in healthy volunteers-an updated review. Br. J. Clin. Pharmacol. 68, 149-168 (2009).
10. Staahl, C., Olesen, A.E., Andresen, T., Arendt-Nielsen, L. & Drewes, A.M. Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers: An updated review. Br. J. Clin. Pharmacol. 68, 322-341 (2009).
11. Simone, D.A., Baumann, T.K. & LaMotte, R.H. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain 38, 99-107 (1989).
12. LaMotte, R.H., Lundberg, L.E. & Torebjork, H.E. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J. Physiol. 448, 749-764 (1992).
13. Liu, M., Max, M.B., Robinovitz, E., Gracely, R.H. & Bennett, G.J. The human capsaicin model of allodynia and hyperalgesia: Sources of variability and methods for reduction. J. Pain Symptom Manage. 16, 10-20 (1998).
14. Hughes, A., Macleod, A., Growcott, J. & Thomas, I. Assessment of the reproducibility of intradermal administration of capsaicin as a model for inducing human pain. Pain 99, 323-331 (2002).
15. Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D. & Julius, D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 389, 816-824 (1997).
16. Schmelz, M. & Kress, M. Topical acetylsalicylate attenuates capsaicin induced pain, flare and allodynia but not thermal hyperalgesia. Neurosci. Lett. 214, 72-74 (1996).
17. Kilo, S., Forster, C., Geisslinger, G., Brune, K. & Handwerker, H.O. Inflammatory models of cutaneous hyperalgesia are sensitive to effects of ibuprofen in man. Pain 62, 187-193 (1995).
18. Eisenach, J.C., Hood, D.D., Curry, R. & Tong, C. Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans. Anesthesiology 86, 1279-1287 (1997).
19. Wallace, M.S., Barger, D. & Schulteis, G. The effect of chronic oral desipramine on capsaicin-induced allodynia and hyperalgesia: A double-blinded, placebo-controlled, crossover study. Anesth. Analg. 95, 973-978 (2002).
20. Desmeules, J.A., Oestreicher, M.K., Piguet, V., Allaz, A.F. & Dayer, P. Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. J. Pharmacol. Exp. Ther. 288, 607-612 (1999).
21. Kinnman, E., Nygårds, E.B. & Hansson, P. Effects of dextromethorphan in clinical doses on capsaicin-induced ongoing pain and mechanical hypersensitivity. J. Pain Symptom Manage. 14, 195-201 (1997).
22. Klein, T., Magerl, W., Hanschmann, A., Althaus, M. & Treede, R.D. Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. Eur. J. Pain 12, 17-29 (2008).
23. Gottrup, H., Bach, F.W., Arendt-Nielsen, L. & Jensen, T.S. Peripheral lidocaine but not ketamine inhibits capsaicin-induced hyperalgesia in humans. Br. J. Anaesth. 85, 520-528 (2000).
24. Gottrup, H., Hansen, P.O., Arendt-Nielsen, L. & Jensen, T.S. Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans. Br. J. Anaesth. 84, 155-162 (2000).
25. Wallace, M.S., Ridgeway, B. 3rd, Leung, A., Schulteis, G. & Yaksh, T.L. Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: Effects on acute thresholds and capsaicin-evoked hyperpathia. J. Clin. Pharmacol. 42, 70-80 (2002).
26. Wallace, M.S., Braun, J. & Schulteis, G. Postdelivery of alfentanil and ketamine has no effect on intradermal capsaicin-induced pain and hyperalgesia. Clin. J. Pain 18, 373-379 (2002).
27. Park, K.M., Max, M.B., Robinovitz, E., Gracely, R.H. & Bennett, G.J. Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain 63, 163-172 (1995).
28. Koppert, W., Ostermeier, N., Sittl, R., Weidner, C. & Schmelz, M. Lowdose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain 85, 217-224 (2000).
29. Wallace, M.S., Laitin, S., Licht, D. & Yaksh, T.L. Concentration-effect relations for intravenous lidocaine infusions in human volunteers: Effects on acute sensory thresholds and capsaicin-evoked hyperpathia. Anesthesiology 86, 1262-1272 (1997).
30. Ando, K., Wallace, M.S., Braun, J. & Schulteis, G. Effect of oral mexiletine on capsaicin-induced allodynia and hyperalgesia: A doubleblind, placebo-controlled, crossover study. Reg. Anesth. Pain Med. 25, 468-474 (2000).
31. Wallace, M.S., Quessy, S. & Schulteis, G. Lack of effect of two oral sodium channel antagonists, lamotrigine and 4030W92, on intradermal capsaicin-induced hyperalgesia model. Pharmacol. Biochem. Behav. 78, 349-355 (2004).
32. Gottrup, H. et al. Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology 101, 1400-1408 (2004).
33. Wang, H. et al. Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects. J. Pain 9, 1088-1095 (2008).
34. Wallace, M.S. & Schulteis, G. Effect of chronic oral gabapentin on capsaicin-induced pain and hyperalgesia: A double-blind, placebo-controlled,crossover study. Clin. J. Pain 24, 544-549 (2008).
35. Andresen, T., Staahl, C., Oksche, A., Mansikka, H., Arendt-Nielsen, L. & Drewes, A.M. Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain. Br. J. Pharmacol. 164, 934-945 (2011).
36. Forster, M. et al. TapCapMentho-a double-blinded, placebocontrolled, cross-over phase I study for evaluation of the effect of 100mg tapentadol IR in two models of thermal and mechanical hyperalgesia. Der Schmerz 27, 1-137 (2013).
37. Wallace, M. et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 107, 785-796 (2007).
38. Kraft, B. et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 109, 101-110 (2008).
39. Wasner, G., Schattschneider, J., Binder, A. & Baron, R. Topical menthol--a human model for cold pain by activation and sensitization of C nociceptors. Brain 127(Pt 5), 1159-1171 (2004).
40. Hatem, S., Attal, N., Willer, J.C. & Bouhassira, D. Psychophysical study of the effects of topical application of menthol in healthy volunteers. Pain 122, 190-196 (2006).
41. Binder, A., Stengel, M., Klebe, O., Wasner, G. & Baron, R. Topical high-concentration (40%) menthol-somatosensory profile of a human surrogate pain model. J. Pain 12, 764-773 (2011).
42. McKemy, D.D., Neuhausser, W.M. & Julius, D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416, 52-58 (2002).
43. Mahn, F., Hullemann, P., Wasner, G., Baron, R. & Binder, A. Topical high-concentration menthol: Reproducibility of a human surrogate pain model. Eur. J. Pain, 18, 1248-1258 (2014).
44. Maier, C. et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities 1236 patients with different neuropathic pain syndromes. Pain 150, 439-450 (2010).
45. Altis, K. et al. Analgesic efficacy of tramadol, pregabalin and ibuprofen in menthol-evoked cold hyperalgesia. Pain 147, 116-121 (2009).
46. Oertel, B.G. & Lotsch, J. Clinical pharmacology of analgesics assessed with human experimental pain models: Bridging basic and clinical research. Br. J. Pharmacol. 168, 534-553 (2013).
47. Lotsch, J., Oertel, B.G. & Ultsch, A. Human models of pain for the prediction of clinical analgesia. Pain 155, 2014-2021 (2014).
48. Rolke, R. et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. Pain 123, 231-243 (2006).
49. Bouhassira, D. et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114, 29-36 (2005).
50. Freynhagen, R., Baron, R., Gockel, U. & Tolle, T.R. painDETECT: A new screening questionnaire to identify neuropathic components in patients with back pain. Curr. Med. Res. Opin. 22, 1911-1920 (2006).
51. Bouhassira, D. et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108, 248-257 (2004).
52. Baron, R., Tolle, T.R., Gockel, U., Brosz, M. & Freynhagen, R. A crosssectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain 146, 34-40 (2009).
53. Cruz-Almeida, Y., Riley, J.L. 3rd & Fillingim, R.B. Experimental pain phenotype profiles in a racially and ethnically diverse sample of healthy adults. Pain Med. 14, 1708-1718 (2013).
54. Attal, N., Rouaud, J., Brasseur, L., Chauvin, M. & Bouhassira, D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 62, 218-225 (2004).
55. Edwards, R.R., Haythornthwaite, J.A., Tella, P., Max, M.B. & Raja, S. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology 104, 1243-1248 (2006).
56. Ranoux, D., Attal, N., Morain, F. & Bouhassira, D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 64, 274-283 (2008).
57. Herrmann, D.N., Pannoni, V., Barbano, R.L., Pennella-Vaughan, J. & Dworkin, R.H. Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies. Muscle Nerve 33, 42-48 (2006).
58. Wasner, G., Kleinert, A., Binder, A., Schattschneider, J. & Baron, R. Postherpetic neuralgia: Topical lidocaine is effective in nociceptordeprived skin. J. Neurol. 252, 677-686 (2005).
59. Yarnitsky, D. et al. Recommendations on terminology and practice of psychophysical DNIC testing. Eur. J. Pain 14, 339 (2010).
60. Bannister, K., Bee, L.A. & Dickenson, A.H. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 6, 703-712 (2009).
61. Yarnitsky, D., Granot, M., Nahman-Averbuch, H., Khamaisi, M. & Granovsky, Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 153, 1193-1198 (2012).
62. Simpson, D.M. et al. Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial. Neurology 74, 413-420 (2010).
63. Freeman, R., Baron, R., Bouhassira, D., Emir, B., Cheung, R. & Murphy, K. Identification of sensory symptom clusters in patients with neuropathic pain based on the neuropathic pain symptom inventory questionnaire. Pain 12, 48 (2011).
64. Freeman, R., Baron, R., Bouhassira, D., Cabrera, J. & Emir, B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain 155, 367-376 (2014).
65. Campbell, C.M. et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 153, 1815-1823 (2012).
66. Martinez, V. et al. The efficacy of a glial inhibitor, minocycline, for preventing persistent pain after lumbar discectomy: A randomized, double-blind, controlled study. Pain 154, 1197-1203 (2013).
67. Kalliomaki, J. et al. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain 154, 761-767 (2013).
68. Hoper, J., Helfert, S., Heskamp, M.L., Maihofner, C.G. & Baron, R. High concentration capsaicin for treatment of peripheral neuropathic pain: Effect on somatosensory symptoms and identification of treatment responders. Curr. Med. Res. Opin. 30, 565-574 (2014).
69. Steigerwald, I. et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: Results of an open-label, phase 3b study. Curr. Med. Res. Opin. 28, 911-936 (2012).
70. Bouhassira, D. et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. Pain 155, 2171-2179 (2014).
71. Kalunian, K.C., Arendt-Nielsen, L., Turkel, C.C. & DeGryse, R. Results from a single center, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy and safety of intra-articular onabotulinumtoxina for osteoarthritis knee pain. Osteoarthritis Cartilage 22, S57-S489 (2014).
72. Arendt-Nielsen, L., Jiang, G.-L., DeGryse, R. & Turkel, C.C. A single center, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy and safety of intra-articular onabotulinumtoxina as treatment for osteoarthritis knee pain: Results from the experimental pain models. Osteoarthritis Cartilage 22, S7-S56 (2014).
73. Reimer, M., Helfert, S.M. & Baron, R. Phenotyping neuropathic pain patients: Implications for individual therapy and clinical trials. Curr. Opin. Support. Palliat. Care 8, 124-129 (2014).
74. Demant, D.T. et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study. Pain (in press).
75. Attal, N. et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol. 17, 1113-e88 (2010).